Literature DB >> 1575069

Benzodiazepine dependence and withdrawal: identification and medical management.

M J Landry1, D E Smith, D R McDuff, O L Baughman.   

Abstract

BACKGROUND: Primary care physicians prescribe benzodiazepines for the treatment of anxiety. Although most patients use the benzodiazepines appropriately, some patients experience benzodiazepine abuse, addiction, or physical dependence, each one of which is a distinct syndrome. Benzodiazepine dependence, which relates to the development of tolerance and an abstinence syndrome, can be produced by three disparate benzodiazepine use patterns. These distinct benzodiazepine use patterns can in turn create distinct withdrawal syndromes. High-dose benzodiazepine use between 1 and 6 months can produce an acute sedative-hypnotic withdrawal syndrome. In contrast, low-dose therapeutic range benzodiazepine use longer than 6 months can produce a prolonged, subacute low-dose benzodiazepine withdrawal syndrome. Daily, high-dose benzodiazepine use for more than 6 months can cause a combination of an acute high-dose benzodiazepine withdrawal and a prolonged, subacute low-dose withdrawal syndrome. In addition, patients may experience syndrome reemergence.
METHODS: A literature search was conducted using the medical subject headings benzodiazepines, substance abuse, substance dependence, substance withdrawal syndrome, and benzodiazepines adverse effects. The years 1970 to the present were reviewed. RESULTS AND
CONCLUSIONS: Medical management for acute benzodiazepine withdrawal includes the graded reduction of the current benzodiazepine dosage, substitution of a long-acting benzodiazepine, and phenobarbital substitution. However, the medical management of benzodiazepine dependence does not constitute treatment of benzodiazepine addiction. Primary care physicians can accept complete, moderate, or limited medical responsibility regarding patients with substance use disorders. However, all physicians should provide diagnostic and referral services.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1575069

Source DB:  PubMed          Journal:  J Am Board Fam Pract        ISSN: 0893-8652


  4 in total

1.  Analysis of tolerance and behavioral/physical dependence during chronic CB1 agonist treatment: effects of CB1 agonists, antagonists, and noncannabinoid drugs.

Authors:  Rajeev I Desai; Ganesh A Thakur; V Kiran Vemuri; Shama Bajaj; Alexandros Makriyannis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2012-11-29       Impact factor: 4.030

Review 2.  Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review.

Authors:  André S Pollmann; Andrea L Murphy; Joel C Bergman; David M Gardner
Journal:  BMC Pharmacol Toxicol       Date:  2015-07-04       Impact factor: 2.483

3.  Dependence potential of quetiapine: behavioral pharmacology in rodents.

Authors:  Hye Jin Cha; Hyun-A Lee; Joon-Ik Ahn; Seol-Hee Jeon; Eun Jung Kim; Ho-Sang Jeong
Journal:  Biomol Ther (Seoul)       Date:  2013-07-30       Impact factor: 4.634

4.  Dependence potential of tramadol: behavioral pharmacology in rodents.

Authors:  Hye Jin Cha; Min Ji Song; Kwang-Wook Lee; Eun Jung Kim; Young-Hoon Kim; Yunje Lee; Won-Keun Seong; Sa-Ik Hong; Choon-Gon Jang; Han Sang Yoo; Ho-Sang Jeong
Journal:  Biomol Ther (Seoul)       Date:  2014-11-30       Impact factor: 4.634

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.